Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.

JJ, Rusthoven; E, Eisenhauer; C, Butts; R, Gregg; J, Dancey; B, Fisher; J, Iglesias

doi:10.1200/jco.1999.17.4.1194

Public

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.

Shared by NobleBlocks on Apr 1, 1999 • 12:00 AM UTC

Authors:

Rusthoven JJ

Eisenhauer E

Butts C

Abstract

Purpose To evaluate the efficacy and safety of the multitargeted antifolate LY231514 (MTA) in patients receiving initial chemotherapy for unresectable, advanced non-small-cell lung cancer (NSCLC).Patients and methods Patients with measurable, advanced NSCLC who had not received previous chemotherapy...

Discussions